Analyst Matthew Taylor from Jefferies reiterated a Buy rating on Lantheus (LNTH – Research Report) and decreased the price target to $130.00 from $140.00.
Matthew Taylor’s rating is based on Lantheus’s strategic initiatives and growth potential despite recent challenges. The company has secured strategic partnerships with key customers, which is expected to strengthen its market position, especially in the PSMA PET market projected to exceed $3.5 billion by the end of the decade. Lantheus’s efforts to expand product availability and maintain premium pricing are seen as positive steps to mitigate competitive disruptions.
Additionally, Lantheus’s pipeline, including promising developments in Alzheimer’s PET Imaging and other diagnostic products, suggests potential for sustainable growth beyond 2025. The recent acquisitions and divestitures, such as Evergreen and the SPECT business, are anticipated to contribute to medium to long-term growth. Despite a reduction in price target due to lower sales expectations for PYLARIFY and EPS dilution, the overall business is viewed as undervalued, justifying the Buy rating.
In another report released today, Truist Financial also maintained a Buy rating on the stock with a $117.00 price target.